EC
CAI

EntryPoint Capital’s Caris Life Sciences CAI Stock Holding History

EntryPoint Capital’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Buy
+33,719
New +$604K 0.15% 255

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EntryPoint Capital's CAI Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Caris Life Sciences (CAI) in Q2 2026: 33,719 shares worth $601K. The stake represents 0.15% of the portfolio and ranks #255 among its holdings.

246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • EntryPoint Capital held 33,719 shares of Caris Life Sciences worth $601K as of Q2 2026.
  • Caris Life Sciences was a new EntryPoint Capital position in Q2 2026.
  • Caris Life Sciences made up 0.15% of EntryPoint Capital's portfolio in Q2 2026, its #255 holding.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.